Interleukin-15, a master piece in the immunological jigsaw of celiac disease

• Published in: Digestive diseases (Basel) Vol. 33; no. 2; p. 122
• Main Authors: Meresse, Bertrand, Korneychuk, Natalia, Malamut, Georgia, Cerf-Bensussan, Nadine
• Format: Journal Article
• Language: English
• Published: Switzerland 01.01.2015
• Subjects: Animals; CD4-Positive T-Lymphocytes - immunology; Celiac Disease - immunology; Cytotoxicity, Immunologic; HLA-DQ Antigens - immunology; Humans; Interleukin-15 - metabolism; Intestinal Mucosa - immunology; Intestinal Mucosa - pathology
• ISSN: 1421-9875
• DOI: 10.1159/000369521

The immune response causing celiac disease (CD) depends on the activation of intestinal CD4+ T cells by gluten-derived peptides presented by HLA-DQ2 or HLA-DQ8 molecules, the main genetic risk factor. However, additional factors are necessary to impair immune tolerance to dietary gluten, to stimulate intraepithelial lymphocytes (IEL) and to induce intestinal damage. Current data point to a central role of interleukin-15 (IL-15). In situ and ex vivo studies indicate that IL-15 stimulates the accumulation and cytotoxic activation of CD8+ T IEL in active CD, and that of the malignant innate-like IEL in type II refractory CD (RCDII). Other studies show that IL-15 impairs the immunoregulatory control of effector T cells, notably CD8+. Recently, animal models have been designed to investigate the respective role of CD4+ T cells and IL-15 in CD. We discuss more particularly our results in such a model, which shows that IL-15 produced in excess in the intestine can cooperate with CD4+ T cells specific for a dietary antigen to trigger a celiac-like enteropathy. In this mouse model, CD4+ T cells activated by dietary ovalbumin secreted IL-2 which, along with IL-15, stimulated the expansion of noncognate intestinal cytotoxic CD8+ T cells containing large amounts of granzyme B. In the presence of IL-15, the latter cells did not respond to regulatory T cells, and accumulated in the intestine close to epithelial damage. On the basis of these data, we propose that, in CD, gluten-specific CD4+ T cells synthesize cytokines that synergize with IL-15 to license the expansion and activation of cytotoxic IEL, which drive tissue damage. We suggest that IL-15 is a meaningful therapeutic target, notably in patients with RCDII in which malignant IEL can respond to IL-15 independently of signals provided by CD4+ T cells.